24/7 Wall Street
15 Oct 2026, 16:45 UTC · 1h ago
AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
Impact · against what's priced in
The article provides no new catalysts for Amgen or Merck, as the dividend coverage and growth metrics discussed are already reflected in the current valuations. While Merck's dividend payout ratio appears alarming relative to 2026 guidance, the price already discounts the Keytruda growth deceleration and patent cliff risks.
- MRK−0.10
Already priced in
- The price assumes
A modest overall revenue growth trajectory that aligns with the company's recent 1.2% year-over-year growth
The article highlights that core Keytruda growth turned negative (-1%) and full-year revenue guidance implies only 2% to 4% growth, confirming the market's refusal to pay for the 12.2% CAGR required by the reverse-DCF.
What MRK's price assumes · Sep 11
